Artwork

İçerik Emma Nichols, PhD and Emma Hitt Nichols tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Emma Nichols, PhD and Emma Hitt Nichols veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !

Iptacopan for PNH, Casgevy and Lyfgenia for Sickle Cell Disease, SGT-003 in Duchenne Muscular Dystrophy, New Fingerstick Blood Collection Device

6:46
 
Paylaş
 

Manage episode 407556896 series 3561458
İçerik Emma Nichols, PhD and Emma Hitt Nichols tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Emma Nichols, PhD and Emma Hitt Nichols veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

Check out our free downloads at nascentmc.com:

See the full write ups for today's episode at nascentmc.com/podcast

Here are the highlights:

1. Iptacopan (Fabhalta) for PNH: The FDA approved iptacopan (Fabhalta), the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH), a condition characterized by the destruction of red blood cells. This approval, based on the APPLY-PNH and APPOINT-PNH studies, marks a significant advancement over existing infusion-based treatments, with most patients experiencing increased hemoglobin levels without the need for blood transfusions.

2. Casgevy and Lyfgenia for Sickle Cell Disease: The FDA approved two gene therapies, Casgevy and Lyfgenia, for sickle cell disease treatment. Casgevy, using CRISPR/Cas9 technology for a one-time stem cell transplant, showed significant effectiveness in reducing severe vaso-occlusive crises in trials. Lyfgenia, employing lentiviral vector gene addition, demonstrated a high rate of resolution in severe vaso-occlusive events, marking a substantial progression in treating this condition.

3. SGT-003 for Duchenne Muscular Dystrophy: SGT-003, a gene therapy for Duchenne muscular dystrophy (DMD), received FDA fast track designation. Utilizing a novel capsid to deliver microdystrophin, this one-time intravenous therapy aims to address the underlying cause of DMD. It follows the accelerated approval of another gene therapy, Elevidys, also for DMD, highlighting advancements in the treatment of this muscular disorder.

4. New Fingerstick Blood Collection Device: The FDA has cleared a new fingerstick blood collection device, MiniDraw™, by Becton Dickinson. This less invasive method for obtaining blood samples aims to transform diagnostic testing by allowing lab-quality results for common blood tests without the need for traditional venous blood draws, offering a more patient-friendly alternative.

See the full write ups for today's episode at nascentmc.com/podcast

Intro and outro music

Garden Of Love by Pk jazz Collective

  continue reading

49 bölüm

Artwork
iconPaylaş
 
Manage episode 407556896 series 3561458
İçerik Emma Nichols, PhD and Emma Hitt Nichols tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Emma Nichols, PhD and Emma Hitt Nichols veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

Check out our free downloads at nascentmc.com:

See the full write ups for today's episode at nascentmc.com/podcast

Here are the highlights:

1. Iptacopan (Fabhalta) for PNH: The FDA approved iptacopan (Fabhalta), the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH), a condition characterized by the destruction of red blood cells. This approval, based on the APPLY-PNH and APPOINT-PNH studies, marks a significant advancement over existing infusion-based treatments, with most patients experiencing increased hemoglobin levels without the need for blood transfusions.

2. Casgevy and Lyfgenia for Sickle Cell Disease: The FDA approved two gene therapies, Casgevy and Lyfgenia, for sickle cell disease treatment. Casgevy, using CRISPR/Cas9 technology for a one-time stem cell transplant, showed significant effectiveness in reducing severe vaso-occlusive crises in trials. Lyfgenia, employing lentiviral vector gene addition, demonstrated a high rate of resolution in severe vaso-occlusive events, marking a substantial progression in treating this condition.

3. SGT-003 for Duchenne Muscular Dystrophy: SGT-003, a gene therapy for Duchenne muscular dystrophy (DMD), received FDA fast track designation. Utilizing a novel capsid to deliver microdystrophin, this one-time intravenous therapy aims to address the underlying cause of DMD. It follows the accelerated approval of another gene therapy, Elevidys, also for DMD, highlighting advancements in the treatment of this muscular disorder.

4. New Fingerstick Blood Collection Device: The FDA has cleared a new fingerstick blood collection device, MiniDraw™, by Becton Dickinson. This less invasive method for obtaining blood samples aims to transform diagnostic testing by allowing lab-quality results for common blood tests without the need for traditional venous blood draws, offering a more patient-friendly alternative.

See the full write ups for today's episode at nascentmc.com/podcast

Intro and outro music

Garden Of Love by Pk jazz Collective

  continue reading

49 bölüm

Tüm bölümler

×
 
Loading …

Player FM'e Hoş Geldiniz!

Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.

 

Hızlı referans rehberi